RIPK1 expression and inhibition in tauopathies: implications for neuroinflammation and neuroprotection
Tauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein. One of the main challenges of these diseases is that they have neither biomarkers nor pharmacological targets to stop the neurodegenerative process. Apart from the neurodegenerative proc...
Saved in:
Main Authors: | Ignacio Silva-Llanes, Enrique Madruga, Ana Martínez, Isabel Lastres-Becker |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2024.1530809/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of hepatocyte RIPK1 in maintaining liver homeostasis during metabolic challenges
by: Weigao Zhang, et al.
Published: (2025-01-01) -
RIPK1 in necroptosis and recent progress in related pharmaceutics
by: Kunhou Yao, et al.
Published: (2025-02-01) -
Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial
by: Norberto Chavez-Tapia, et al.
Published: (2025-01-01) -
Therapeutic targeting of obesity-induced neuroinflammation and neurodegeneration
by: Jialiu Zeng, et al.
Published: (2025-01-01) -
Understanding retinal tau pathology through functional 2D and 3D iPSC-derived in vitro retinal models
by: Lorenza Mautone, et al.
Published: (2025-01-01)